{"id":262329,"date":"2025-12-31T11:00:24","date_gmt":"2025-12-31T11:00:24","guid":{"rendered":"https:\/\/www.worldsocialism.org\/spgb\/?post_type=snippet&#038;p=262329"},"modified":"2025-12-30T17:33:09","modified_gmt":"2025-12-30T17:33:09","slug":"whose-welfare","status":"publish","type":"snippet","link":"https:\/\/www.worldsocialism.org\/spgb\/snippet\/whose-welfare\/","title":{"rendered":"Whose &#8216;welfare&#8217;?"},"content":{"rendered":"<p>Around 7 million people in the UK have asthma, of whom some 58,000 suffer &#8216;really scary&#8217; attacks that require hospitalisation. These severe sufferers will be heartened to know that Depemokimab,, a new &#8216;ultra-long acting&#8217; medicine that only needs to be taken twice a year, has just received UK approval, having shown it can reduce the number of severe attacks by 72 percent (<em>Sunday Times,<\/em> 28 Dec).<\/p>\n<p>An &#8216;important step forward&#8217; then, showing how capitalism has our welfare at heart? Er, not entirely. The paper added that the drug &#8216;will reduce the time patients need to take off work, as well as free up NHS resources&#8217;. Money priorities linger like a bad smell, even over positive news stories.<\/p>\n","protected":false},"template":"","class_list":["post-262329","snippet","type-snippet","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.worldsocialism.org\/spgb\/wp-json\/wp\/v2\/snippet\/262329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldsocialism.org\/spgb\/wp-json\/wp\/v2\/snippet"}],"about":[{"href":"https:\/\/www.worldsocialism.org\/spgb\/wp-json\/wp\/v2\/types\/snippet"}],"wp:attachment":[{"href":"https:\/\/www.worldsocialism.org\/spgb\/wp-json\/wp\/v2\/media?parent=262329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}